| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/27/2023 | -23.66% | Credit Suisse | $2 → $1 | Downgrades | Neutral → Underperform |
| 11/21/2022 | 129.01% | RBC Capital | $7 → $3 | Downgrades | Outperform → Sector Perform |
| 11/17/2022 | 52.67% | Credit Suisse | $5.5 → $2 | Downgrades | Outperform → Neutral |
| 11/16/2022 | 205.34% | Raymond James | $6 → $4 | Maintains | Strong Buy |
| 11/11/2022 | 14.5% | Stephens & Co. | $2.25 → $1.5 | Maintains | Equal-Weight |
| 08/19/2022 | 281.68% | Barclays | $7 → $5 | Maintains | Overweight |
| 08/15/2022 | 358.02% | Raymond James | $8 → $6 | Maintains | Strong Buy |
| 07/22/2022 | 90.84% | Jefferies | $9 → $2.5 | Downgrades | Buy → Hold |
| 07/05/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 06/21/2022 | 167.18% | Stephens & Co. | $5.5 → $3.5 | Downgrades | Overweight → Equal-Weight |
| 03/31/2022 | 510.69% | Raymond James | $12 → $8 | Maintains | Strong Buy |
| 03/31/2022 | 587.02% | RBC Capital | $16 → $9 | Maintains | Outperform |
| 03/30/2022 | 281.68% | Truist Securities | $10 → $5 | Maintains | Buy |
| 03/30/2022 | 358.02% | Deutsche Bank | $12.5 → $6 | Maintains | Buy |
| 03/30/2022 | 434.35% | Stephens & Co. | $11.5 → $7 | Maintains | Overweight |
| 03/30/2022 | 434.35% | Barclays | $16 → $7 | Maintains | Overweight |
| 03/30/2022 | 625.19% | Credit Suisse | $12 → $9.5 | Maintains | Outperform |
| 03/29/2022 | 319.85% | B of A Securities | $10 → $5.5 | Downgrades | Buy → Neutral |
| 11/23/2021 | 816.03% | Raymond James | $15 → $12 | Maintains | Strong Buy |
| 05/24/2021 | 968.7% | JP Morgan | → $14 | Initiates Coverage On | → Neutral |
| 05/24/2021 | 1045.04% | Jefferies | → $15 | Initiates Coverage On | → Buy |
| 05/24/2021 | 1045.04% | Raymond James | → $15 | Initiates Coverage On | → Strong Buy |
| 05/24/2021 | 930.53% | Deutsche Bank | → $13.5 | Initiates Coverage On | → Buy |
| 05/24/2021 | 1121.37% | Credit Suisse | → $16 | Initiates Coverage On | → Outperform |
| 05/24/2021 | 1197.71% | BMO Capital | → $17 | Initiates Coverage On | → Outperform |
| 05/24/2021 | 1121.37% | RBC Capital | → $16 | Initiates Coverage On | → Outperform |
| 05/24/2021 | 1426.72% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 05/24/2021 | 1045.04% | Truist Securities | → $15 | Initiates Coverage On | → Buy |
What is the target price for Aveanna Healthcare Hldgs (AVAH)?
The latest price target for Aveanna Healthcare Hldgs (NASDAQ: AVAH) was reported by Credit Suisse on January 27, 2023. The analyst firm set a price target for $1.00 expecting AVAH to fall to within 12 months (a possible -23.66% downside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aveanna Healthcare Hldgs (AVAH)?
The latest analyst rating for Aveanna Healthcare Hldgs (NASDAQ: AVAH) was provided by Credit Suisse, and Aveanna Healthcare Hldgs downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for Aveanna Healthcare Hldgs (AVAH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aveanna Healthcare Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aveanna Healthcare Hldgs was filed on January 27, 2023 so you should expect the next rating to be made available sometime around January 27, 2024.
Is the Analyst Rating Aveanna Healthcare Hldgs (AVAH) correct?
While ratings are subjective and will change, the latest Aveanna Healthcare Hldgs (AVAH) rating was a downgraded with a price target of $2.00 to $1.00. The current price Aveanna Healthcare Hldgs (AVAH) is trading at is $1.31, which is out of the analyst's predicted range.